TOKYO & PALO ALTO, Calif.--(BUSINESS WIRE)--Heartseed Inc. ("Heartseed"), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc. ("I Peace"), a ...
CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, ...
12don MSN
Multi-scale analysis reveals FGFR1 inhibition as effective strategy against cardiac fibrosis
Through a comprehensive approach combining transcriptomic profiling, histological analysis, and functional validation in ...
Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) say that it is now possible for the first time to monitor the functional development and maturation of ...
Novel technology returns cardiomyocytes to a stem cell-like state to promote their proliferation and regeneration in an in vitro study. Researchers at the University of Houston (TX, USA) have ...
Heartseed Inc. raised ¥2 billion (US$14.3 million) in a series D round to continue the phase I/II Lapis trial of its allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocytes for heart ...
A recent study published in Scientific Reports elucidated the molecular mechanisms of drug-induced regulation of growth differentiation factor 15 (GDF15). GDF15 has emerged as a driver of cachexia ...
University of Alabama at Birmingham researchers, led by Jianyi “Jay” Zhang, M.D., Ph.D., and Lei Ye, M.D., Ph.D., generated the human leukocyte antigen-knockout ...
Researchers have shown that cardiac scar tissue (fibroblasts) can be directly reprogrammed to heart muscle cells (cardiomyocytes) in mice. By treating mice post-heart attack with a virus carrying ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback